We are monitoring the impact of COVID-19 on Europe Preventive Vaccine Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 117
Share on
Share on

Europe Preventive Vaccine Market Research Report - By Vaccine Type, End User and Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Trends & Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 117
Pages: 145

Europe Preventive Vaccine Market Size (2020 to 2025)

The size of the European Preventive Vaccines market has been estimated at USD 9.99 Billion in 2020 and is poised to reach USD 17.83 billion by 2025, growing at a CAGR of 12.28% between 2020 to 2025.

Recently there has been substantial growth in the vaccine market with the rising incidences of cancer & HIV cases. World Health Organization growth estimations indicate the market may increase in value to almost 17.83 billion in 2023, with the arrival of new therapeutic, preventive, and adult vaccines.

The vaccine market is quite different from any other product market, having distinct features with the increased complexity of assessing, understanding prices and procurement. Although it is a small market compared to the pharmaceutical market, we cannot dismiss the fact that it is growing rapidly. There are currently around 120 new vaccines in the pipeline of various multinational companies worldwide and are set to hit the market in the coming years. While the vaccine market is concentrated on both supply and demand sides, it is mostly dependent on public purchasers and donor policies.

The introduction of new vaccines for every other disease is aiding the growth of the vaccine market. Also, a rise in the frequency of infectious diseases like tuberculosis, hepatitis, diphtheria, and pneumococcal diseases across the globe has increased the usage of vaccines. Invested from governments for vaccine development, increase in funding by the major market players, rising occurrence of disease, technological advancements decreasing the new vaccine development time drastically, initiatives by NGO’s are some of the factors that are propelling the growth of vaccines

However, few factors are restraining the growth of the vaccine market, huge capital expenditures, and stringent regulatory policies by the governments, the massive cost associated with treatment.

This research report segmented and sub-segmented the European Preventive Vaccines Market into the following categories:

By Vaccine Type:

  • Live, Attenuated Vaccines
  • Inactivated Vaccines             
  • Toxoid Vaccines    
  • Subunit Vaccines  
  • Conjugate Vaccines             
  • DNA Vaccines         
  • Recombinant Vector Vaccines          

By End-User:

  • Pediatric Vaccine
    • Pneumococcal
    • MMR
    • Varicella
    • Hepatitis
    • Poliovirus
    • HIB
    • Others
  • Adult Vaccines      
    • Influenza
    • Cervical Cancer
    • Hepatitis
    • Zoster
    • Others

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Historically many multinational vaccine companies have been investing huge sums in research and development, resulting in market innovations.

Companies playing a dominating role in the recent past in the European Preventive Vaccine Market are GlaxoSmithKline, PLC, Bavarian Nordic, Merck and Company, CSL Limited, Novartis AG, Emergent BioSolutions Inc., Johnson and Johnson, MedImmune, LLC., Pfizer, Inc. and Sanofi Pasteur.

  1. Introduction

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

  1. Research Methodology

                2.1 Introduction                                                              

                2.2 Analysis Design                                                         

                2.3 Research Phases                                                      

                                2.3.1 Secondary Research                                            

                                2.3.2 Primary Research                                 

                                2.3.3 Econometric Modelling                                     

                                2.3.4 Expert Validation                                  

                2.4 Study Timeline                                                          

  1. Overview

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

  1. Market Segmentation

                5.1 By Vaccine Type                                                       

                                5.1.1 Live, Attenuated Vaccines                                

                                5.1.2 Inactivted Vaccines                                             

                                5.1.3 Toxoid Vaccines                                    

                                5.1.4 Subunit vaccines                                  

                                5.1.5 Conjugate vaccines                                             

                                5.1.6 DNA vaccines                                         

                                5.1.7 Recombinant vector vaccines                                          

                5.2 By End User                                               

                                5.2.1 Paediatric Vaccine                                

                                                5.2.1.1 Pneumococcal                   

                                                5.2.1.2 MMR                     

                                                5.2.1.3 Varicella               

                                                5.2.1.4 Hepatitis                              

                                                5.2.1.5 Poliovirus                             

                                                5.2.1.6 HIB                         

                                                5.2.1.7 Others                  

                                5.2.2 Adult Vaccines                                      

                                                5.2.2.1 Influenza                             

                                                5.2.2.2 Cervical Cancer                 

                                                5.2.2.3 Hepatitis                              

                                                5.2.2.4 Zoster                   

                                                5.2.2.5 Others                  

  1. Geographical Analysis

                6.1 Introduction                                                              

                6.2 U.K                                                

                6.3 Spain                                                             

                6.4 Germany                                                     

                6.5 Italy                                                               

                6.6 France                                                          

  1. Strategic Analysis

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                      

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                               

                                7.2.5 Competitive Rivalry within the Industry                                      

  1. Market Leaders' Analysis

                8.1 GlaxoSmithKline, plc.                                                             

                                8.1.1 Overview                                

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                            

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Merck and Company                                                              

                8.3 Bavarian Nordic                                                        

                8.4 CSL Limited                                                 

                8.5 Emergent BioSolutions Inc.                                                  

                8.6 Novartis AG                                                

                8.7 Johnson and Johnson                                                             

                8.8 MedImmune, LLC                                                    

                8.9 Pfizer, Inc.                                                   

                8.10 Sanofi Pasteur                                                        

  1. Competitive Landscape

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                        

                9.3 Agreements, collaborations and Joint Ventures                                                          

                9.4 New Product Launches                                                          

  1. Expert Opinions

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

     Appendix                                                                           

  1. List of Tables
  2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Preventive Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  2. Europe Preventive Vaccines Market, By Vaccine Type, From 2020 to 2025 (USD Billion)
  3. Europe Live, Attenuated Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  4. Europe Inactivated Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  5. Europe Toxoid Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  6. Europe Subunit vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  7. Europe Conjugate vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  8. Europe DNA vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  9. Europe Recombinant vector vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  10. Europe Preventive Vaccines Market, By End User, From 2020 to 2025 (USD Billion)
  11. Europe Paediatric Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  12. Europe Adult Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  13. Europe Paediatric Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  14. Europe Pneumococcal Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  15. Europe MMR Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  16. Europe Varicella Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  17. Europe Hepatitis Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  18. Europe Poliovirus Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  19. Europe HIB Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  20. Europe Other Paediatric Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  21. Europe Adult Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  22. Europe Influenza Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  23. Europe Cervical Cancer Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  24. Europe Hepatitis Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  25. Europe Zoster Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  26. Europe Other Adult Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  27. U.K. Preventive Vaccines Market, By Vaccine Type, From 2020 to 2025 (USD Billion)
  28. U.K. Preventive Vaccines Market, By End User, From 2020 to 2025 (USD Billion)
  29. Germany Preventive Vaccines Market, By Vaccine Type, From 2020 to 2025 (USD Billion)
  30. Germany Preventive Vaccines Market, By End User, From 2020 to 2025 (USD Billion)
  31. France Preventive Vaccines Market, By Vaccine Type, From 2020 to 2025 (USD Billion)
  32. France Preventive Vaccines Market, By End User, From 2020 to 2025 (USD Billion)
  33. Italy Preventive Vaccines Market, By Vaccine Type, From 2020 to 2025 (USD Billion)
  34. Italy Preventive Vaccines Market, By End User, From 2020 to 2025 (USD Billion)
  35. Spain Preventive Vaccines Market, By Vaccine Type, From 2020 to 2025 (USD Billion)
  36. Spain Preventive Vaccines Market, By End User, From 2020 to 2025 (USD Billion)
  37. U.K. Paediatric Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  38. Germany Paediatric Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  39. France Paediatric Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  40. Italy Paediatric Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  41. Spain Paediatric Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  42. U.K. Adult Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  43. Germany Adult Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  44. France Adult Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  45. Italy Adult Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  46. Spain Adult Vaccines Market, By Type, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample